November 25, 2024 07:27 GMT
HEALTHCARE: Glaxo (GSK: A2/A): Blenrep - Good News
HEALTHCARE
Not a spread mover but keeps the ball rolling
- Blenrep is GSK's competitor to Darzalex in the Myeloma space
- JNJ sells $11.6bn of Darzalex annually
- Peak sales of Blenrep are expected to be over $3bn according to GSK's CCO
- Blenrep has just had its 6th "major regulatory filing acceptance this year"
- US decision expected by 23 July 2025
Media Link
54 words